Literature DB >> 30967471

Overview of the Components of Cardiac Metabolism.

Elizabeth A Hausner1, Susan A Elmore1, Xi Yang2.   

Abstract

Metabolism in organs other than the liver and kidneys may play a significant role in how a specific organ responds to chemicals. The heart has metabolic capability for energy production and homeostasis. This homeostatic machinery can also process xenobiotics. Cardiac metabolism includes the expression of numerous organic anion transporters, organic cation transporters, organic carnitine (zwitterion) transporters, and ATP-binding cassette transporters. Expression and distribution of the transporters within the heart may vary, depending on the patient's age, disease, endocrine status, and various other factors. Several cytochrome P450 (P450) enzyme classes have been identified within the heart. The P450 hydroxylases and epoxygenases within the heart produce hydroxyeicosatetraneoic acids and epoxyeicosatrienoic acids, metabolites of arachidonic acid, which are critical in regulating homeostatic processes of the heart. The susceptibility of the cardiac P450 system to induction and inhibition from exogenous materials is an area of expanding knowledge, as are the metabolic processes of glucuronidation and sulfation in the heart. The susceptibility of various transcription factors and signaling pathways of the heart to disruption by xenobiotics is not fully characterized but is an area with implications for disruption of normal postnatal development, as well as modulation of adult cardiac health. There are knowledge gaps in the timelines of physiologic maturation and deterioration of cardiac metabolism. Cross-species characterization of cardiac-specific metabolism is needed for nonclinical work of optimum translational value to predict possible adverse effects, identify sensitive developmental windows for the design and conduct of informative nonclinical and clinical studies, and explore the possibilities of organ-specific therapeutics.
Copyright © 2019 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30967471     DOI: 10.1124/dmd.119.086611

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Changes in the Left Ventricular Eicosanoid Profile in Human Dilated Cardiomyopathy.

Authors:  Deanna K Sosnowski; K Lockhart Jamieson; Ahmed M Darwesh; Hao Zhang; Hedieh Keshavarz-Bahaghighat; Robert Valencia; Anissa Viveiros; Matthew L Edin; Darryl C Zeldin; Gavin Y Oudit; John M Seubert
Journal:  Front Cardiovasc Med       Date:  2022-05-19

Review 2.  A Review of Cardiovascular Toxicity of Microcystins.

Authors:  Linghui Cao; Isaac Yaw Massey; Hai Feng; Fei Yang
Journal:  Toxins (Basel)       Date:  2019-08-30       Impact factor: 4.546

3.  Metabolomic Analysis of the Ameliorative Effect of Enhanced Proline Metabolism on Hypoxia-Induced Injury in Cardiomyocytes.

Authors:  Jiacheng Wang; Zhimin Xue; Chunting Hua; Jun Lin; Zhida Shen; Yinjing Song; Hangying Ying; Qingbo Lv; Meihui Wang; Binquan Zhou
Journal:  Oxid Med Cell Longev       Date:  2020-11-26       Impact factor: 6.543

Review 4.  Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets.

Authors:  Misganaw Asmamaw Mengstie; Endeshaw Chekol Abebe; Awgichew Behaile Teklemariam; Anemut Tilahun Mulu; Assefa Agegnehu Teshome; Edgeit Abebe Zewde; Zelalem Tilahun Muche; Muluken Teshome Azezew
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

5.  Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model.

Authors:  Rosalinda Madonna; Stefania Moscato; Enza Polizzi; Damiana Pieragostino; Maria Concetta Cufaro; Piero Del Boccio; Francesco Bianchi; Raffaele De Caterina; Letizia Mattii
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

6.  Transcriptional Regulation of Drug Metabolizing CYP Enzymes by Proinflammatory Wnt5A Signaling in Human Coronary Artery Endothelial Cells.

Authors:  Tom Skaria; Esther Bachli; Gabriele Schoedon
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.